Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

SQI Diagnostics Inc V.SQD.H

SQI Diagnostics Inc. is a Canada-based company that is focused on lung health. The Company is engaged in the development and manufacturing of respiratory health and precision medicine tests that run on its fully automated systems. Its clinical solutions include Rapid Acute Lung Injury Diagnostic (RALI-Dx), lung transplant diagnostics, COVID-19 testing and surveillance testing solutions. Its RALI-Dx IL-6 Severity Triage Test and the RALI-fast IL-6 Severity Triage point of care (POC) Test each help clinicians identify which patients with SARS-CoV-2 are predicted to have a severe inflammatory response and should or should not be admitted to the hospital. Its RALI-Dx delivers results from the lab in less than an hour while RALI-fast delivers results at the patient point-of-care in about 15 minutes. The Company’s TORdx LUNG Test measures inflammation at the molecular level to assess the health of the donor lung. The Company is also focused on its organ transplant pipeline of products.


TSXV:SQD.H - Post by User

Comment by mercedesmanon Mar 23, 2022 3:45pm
158 Views
Post# 34538964

RE:SQI's Rali-Dx & Rali-fast make perfect companion diagnostics

RE:SQI's Rali-Dx & Rali-fast make perfect companion diagnostics
FactFinder1994 wrote: for guiding various theraputics.  Targets like IL-6 & IL-10 are of key importance.  This opportunity plays well beyond Covid-19 and rather is applicible for any respiratory query.  Determining the path (triaging) of a patient is of key omportance to attending physicians.     


                                                                                           Hemoperfusion as a Potential Treatment for Critically Ill COVID-19 Patients with Cytokine Storm karger.com • 6 min read                                                                           



I think the triaging with Rali-Dx is very UNDERAPPRECIATED  by potential investors.

If you have a chest/lung infection...a garden variety test will tell you whether it's Covid or Pneumonia etc.  BUT  more importantly, one really should want to know ...is it a serious infection with bad inflammatory markers that increase your odds of ending up in the hosptital or ICU?  That is what you really want to know, and presumably what the Rali-Dx test will determine.  Why is that important? Number 1  there are early treatments you can get to dramatically reduce the odds of ICU admission or worse.

Too me this is the third new REVENUE PILLAR that is VERY MUCH underappreciated.

The three pillars (not including UHN/Transplant diagnostics)

1.  Mobile PCR testing (focused on the sticky users like mines and Production crews that cannot afford anyone to slip through, but even so, I anticipate a variant wave and a fall wave)

2. DTC Antibody testing  (Covid antibodies sufficeint?, do I need more boosting?, etc.)

and NOW ....

3. If a PCR or multiplex tests says that you have Covid or pneumonia...now what?....you need to know how bad is it?  So that you can take additional steps immediately.  I know I would pay for that info.

  • The revenue taps have turned on re: # 1  (with purchase of existing , hit the gorund running, business)

  • The Revenue taps re: # 2 should turn on in April (Azova)

  • The third revenue tap starts...?  (hard to believe, but maybe even more exciting than # 1 and # 2).


What till the uninitiated start to see how fast the revenues are apt grow !  ($ 3.6M+ in Q2 is just the start)

Now they need to bring on some serious IR.

I'm looking forward to them getting the word out there ! ... so that there are more than 20 investors (including the billionaire insiders, some employees, and six SH posters)

It's time !



MM





<< Previous
Bullboard Posts
Next >>